Ipamorelin vs Sermorelin

Almost every page ranking for this comparison answers a clinical question. The question a caller is actually about to create for your front desk is a regulatory one.

Ipamorelin acetate and sermorelin are both peptides marketed in connection with growth hormone, and in the United States they sit in entirely different regulatory positions. The Food and Drug Administration lists ipamorelin acetate twice on its Category 2 page of bulk substances that may present significant safety risks. Sermorelin appears in none of the three categories FDA maintains under section 503A of the Federal Food, Drug, and Cosmetic Act. Sermorelin once had an approved product, Geref, which EMD Serono asked FDA to withdraw in 2008 and which FDA later determined was not withdrawn for reasons of safety or effectiveness. Ipamorelin never had one. None of that is a clinical judgment, and all of it is on federal websites that a prospective patient can read before she dials.

Ipamorelin acetate appears twice on FDA's Category 2 page; sermorelin appears on none of the three 503A lists

FDA's page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, lists ipamorelin acetate in two separate tables. In the first, it is in category 2 under the 503B interim policy, added 29 September 2023. In the second, headed "Bulk drug substances nominated but withdrawn," ipamorelin acetate appears again because its nomination was withdrawn by the nominator. FDA's own row annotation says the substance "also appears in the table above because it is in category 2 under the 503B interim policy."

FDA's consolidated 503A category document, updated 14 May 2026, lists every substance in each of the three categories. Category 1 runs to roughly four dozen entries, including nicotinamide adenine dinucleotide, glutathione, enclomiphene citrate and vasoactive intestinal peptide. Category 2 lists six: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. Category 3 runs to several hundred, and includes GHRP-2 and GHRP-6. Those two sit differently under the other statutory pathway: FDA's Category 2 page places both GHRP-2 and GHRP-6 in category 2 under the 503B interim policy, added 29 September 2023. A substance's position is pathway-specific, and quoting one pathway as though it were the whole picture is how most summaries go wrong.

Sermorelin is not on any of the three. That is a factual observation about the current document, and it is at odds with a claim repeated across commercial peptide sites that sermorelin "sits in Category 1." Readers should check the FDA document themselves rather than take either characterization on trust; it is a short PDF and it is dated on its face.

FDA's stated concerns about ipamorelin acetate are immunogenicity, characterization, serious adverse events including death by the intravenous route, and missing data elsewhere

FDA does not leave its reasoning implicit. The agency's Category 2 entry for ipamorelin acetate gives four specific concerns.

• Compounded drugs containing ipamorelin acetate may pose a risk for immunogenicity for certain routes of administration, due to the potential for aggregation or peptide-related impurities.

• Ipamorelin acetate contains unnatural amino acids, which FDA says add to the complexity of peptide characterization.

• A study published in the literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.

• For certain other injectable routes, FDA states it has not identified safety-related information and therefore "lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes."

The fourth point is the one most often lost in summary. Absence of a safety signal is not evidence of safety, and FDA is saying so explicitly. A practice that describes ipamorelin as having "no reported safety concerns" is describing the absence of data as though it were a finding.

Sermorelin had an approved product until 2009, and FDA determined the withdrawal was not for safety or effectiveness

Sermorelin acetate was marketed as Geref. EMD Serono requested withdrawal of NDA 20-443 in a letter dated 2 December 2008, and of NDA 19-863 in a letter dated 12 December 2008. FDA announced the withdrawal of NDA 19-863 and NDA 20-443 in the Federal Register of 19 May 2009, effective 18 June 2009. In a subsequent Federal Register notice of 4 March 2013, FDA formally determined that the Geref products "were not withdrawn from sale for reasons of safety or effectiveness."

That 2013 determination matters and is frequently over-read. Its legal function is to allow abbreviated new drug applications to reference the withdrawn listing. It is a statement about why the product left the market, not a statement that any currently available sermorelin preparation is approved. There is no FDA-approved sermorelin product in the United States today, and a compounded preparation is not an approved finished drug regardless of how it is described in marketing copy.

Removal from Category 2 is the nominator withdrawing, not FDA clearing

A recurring genre of commercial article announces that peptides have been "removed from Category 2" and are therefore available again. FDA's own page frames the same event differently. The heading is "Bulk drug substances nominated but withdrawn," and the sentence beneath it reads that these substances "were withdrawn by the nominators."

The list under that heading includes AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide, epitalon, GHK-Cu for injectable routes, ipamorelin acetate, KPV, PEG-MGF, melanotan II, MOTS-C, selank acetate, semax, thymosin alpha-1 and TB-500. FDA retained its safety language for every one of them on the same page.

Reading that as clearance inverts it. A withdrawn nomination is a nomination that will not be evaluated. The substance does not move toward the 503A bulks list; it steps out of the queue for it.

Section 503A allows three routes, and a category listing is not one of them

The statutory routes are the part that determines what a clinic can actually source, and they are the part most comparison articles leave out.

FDA states that state-licensed physicians and pharmacists compounding under section 503A may only use bulk drug substances that comply with an applicable United States Pharmacopeia or National Formulary monograph where one exists, or are components of FDA-approved drug products where no such monograph exists, or appear on FDA's 503A bulks list where neither of the first two applies. The bulks list itself is codified at 21 CFR 216.23. The February 2019 final rule placed six substances on it, declined four others, and took effect on 21 March 2019.

Category 1 is not a fourth route. It is an interim enforcement posture: FDA says it does not intend to take action against a compounder using a Category 1 substance, provided the conditions in its guidance are met, while the substance is evaluated. FDA has also stated it does not intend to place substances nominated on or after 7 January 2025 into these categories at all, which means the interim framework is closing rather than expanding.

The practical consequence for a clinic is narrow and concrete. Which of the three statutory routes a given preparation relies on is a question the compounding pharmacy should be able to answer in writing. If nobody at the practice has ever asked, nobody at the practice knows.

What a longevity clinic's front desk can say when a caller asks which peptide is better

A front desk cannot answer the clinical question, and should not try. It also should not answer the regulatory question wrong, because a wrong answer delivered by a practice about an unapproved drug is a marketing claim, not a mistake.

What it can do is route correctly, and routing requires recognizing the question. A caller asking "do you do ipamorelin" and a caller asking "what would you put me on" are two different conversations arriving on the same line. The first is a sourcing question with a documentary answer the clinical team holds. The second is a consultation.

Illustrative model - not a client result or guarantee. Picture a clinic that takes peptide inquiries across a twelve-hour span and staffs the phone for eight of them. Every inquiry in the uncovered four hours reaches the same recording. The model assumes nothing about the clinic's conversion rate or its pricing. It assumes only that the question gets asked outside office hours as often as inside them, which is what a call log will show if anyone pulls it. The number in that gap is the clinic's own; TTR has not measured it for anyone.

A structured intake layer does not diagnose and does not recommend. It recognizes a regulatory question, captures which peptide was named, and routes to the clinician who can answer, at the hour the caller happened to be reading FDA's website. That is what Aurora, our Vitality Specialist, is built to do on longevity and peptide lines.

Frequently asked questions

Is ipamorelin FDA approved? No. There is no FDA-approved ipamorelin product. FDA lists ipamorelin acetate in category 2 under its 503B interim policy, added 29 September 2023, and separately records it among bulk drug substances whose nominations were withdrawn by the nominators.

Is sermorelin FDA approved? Not currently. Sermorelin acetate was approved as Geref. FDA withdrew NDA 19-863 and NDA 20-443 effective 18 June 2009, following EMD Serono's withdrawal requests of 2 December 2008 for NDA 20-443 and 12 December 2008 for NDA 19-863. FDA determined in 2013 that the withdrawal was not for reasons of safety or effectiveness.

Does removal from Category 2 mean a peptide is now allowed? FDA's page describes those substances as "nominated but withdrawn" and states the nominations were withdrawn by the nominators. FDA retained its safety language for each. A withdrawn nomination is not an approval and does not place a substance on the 503A bulks list.

What determines whether a compounding pharmacy can use a bulk substance under 503A? FDA states three conditions: compliance with an applicable USP or NF monograph where one exists; being a component of an FDA-approved drug product where no monograph exists; or appearing on the 503A bulks list, codified at 21 CFR 216.23.

Which peptides are in 503A Category 2 right now? As of FDA's 14 May 2026 document: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. GHRP-2 and GHRP-6 sit in 503A Category 3, nominated without adequate support, and separately in category 2 under the 503B interim policy.

Where this fits

A caller who has read a federal register notice before dialing is not a difficult caller. She is an informed one, and she is the most valuable inquiry a longevity practice receives. The failure mode is not that the front desk lacks a pharmacology degree. It is that nobody decided in advance what the front desk is permitted to say, so four people say four things. The same pattern shows up in how practices handle the BPC-157 question, in the peptide pricing conversation, in callers who cannot name the program they want, in telehealth eligibility on the first call, and in how diagnostic panel pricing gets explained. All of them are the same leak point wearing different clothes.

You already publish a peptide menu. Your clinical team already knows which preparations it will and will not source. The open question is whether the person answering the phone at 7pm knows the same thing.

This article describes regulatory status from primary federal sources. It is not medical advice and does not recommend any therapy. Decisions about peptide therapy belong with a licensed clinician.

References

• U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," content current as of 22 April 2026 - ipamorelin acetate category 2 (503B) entry dated 29 September 2023, the nominated-but-withdrawn table, and the stated safety concerns quoted above.

• U.S. Food and Drug Administration, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act," updated 14 May 2026 (fda.gov/media/94155) - the three category lists.

• U.S. Food and Drug Administration, "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act," content current as of 14 May 2026 - the three statutory routes, the category definitions, and the 7 January 2025 nomination cutoff.

• Federal Register, 19 May 2009 (74 FR 23407) - withdrawal of NDA 19-863 and NDA 20-443, effective 18 June 2009.

• Federal Register, 4 March 2013 - "Determination That GEREF (Sermorelin Acetate) Injection ... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness," including EMD Serono's request letters of 2 December 2008 (NDA 20-443) and 12 December 2008 (NDA 19-863).

• 21 CFR 216.23 - bulk drug substances that can be used to compound drug products in accordance with section 503A; February 2019 final rule, effective 21 March 2019.

• Keyword volume, cost-per-click and difficulty pulled September 2026 from the Ubersuggest keyword dataset, United States, English.

Next Step

If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline is leaking revenue. We quantify this for your practice in a 30-minute Intake Leak Audit.

• Request an Intake Leak Audit: expand@thethinkingrobot.com

• Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664.